Cantel Medical Corp

Cantel Medical — Investor Presentation (September 2011)

23 slides from Cantel Medical's investor presentation, Sep 13, 2011

  1. Slide 1: Infection Control Matters

    Cantel Medical Corp. (NYSE: CMN) Infection Control Matters™ 09-13-2011 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements. All forward-looking statements involve risks and uncertainties, including, without limitation, the risks detailed in the Company’s filings and repor

  2. Slide 2: $345M NYSE Leader in Infection Prevention & Control

    2 Cantel Medical Corp. $345M NYSE Leader in Infection Prevention & Control1 Pure-play in a ~$35 billion Infection Prevention & Control Market (“IP&C”) Large, highly fragmented opportunities for growth and further expansion 17 acquisitions since 2001 have re-shaped the company Recession buffered mark

  3. Slide 3: ~$35B Global Infection Prevention & Control Market

    3 Cantel Medical Corp. ~$35B Global Infection Prevention & Control Market Global IP&C Market (2006 US$M) U.S. Infection Prevention & Control Market (US$B) Forecast CAGR% 2006-2016 = 3.9% Infections in Medical Facilities are a Rapidly Growing Problem Annually, 2.3 Million People Acquire Infections in

  4. Slide 4: Fragmented Nature of Infection Prevention & Control

    4 Cantel Medical Corp. Fragmented Nature of Infection Prevention & Control Indicates Cantel product offering Key strategic priorities Disinfectants & Cleaners Disposables Masks / Headwear Air & Water Quality Protective Apparel Brushes Disposable kits / trays Face shields Air filtration systems Apron

  5. Slide 5: Healthcare Reform Creates Greater Emphasis in IP&C

    5 Cantel Medical Corp. Healthcare Reform Creates Greater Emphasis in IP&C Financial Penalties to Hospitals1 Preventable Readmissions – Estimated $25 billion cost to the system Beginning 2012, Medicare will stop paying hospitals for preventable readmissions tied to heart failure or pneumonia Beginnin

  6. Slide 6: Three Synergistic Platforms

    6 Cantel Medical Corp. Three Synergistic Platforms Infection Prevention & Control Focus Healthcare & Life Sciences Orientation IP&C Device Management Endoscopy & Renal Dialysis Medivators/Byrne; Minntech Purification & Filtration Water Treatment & Therapeutic Filters Mar Cor Purification; Minntech D

  7. Slide 7: Well-Balanced Portfolio with Emphasis on Endoscopy

    7 Cantel Medical Corp. Well-Balanced Portfolio with Emphasis on Endoscopy Twelve Months Ended April 30, 20111 1 “All Other” includes Therapeutic Filtration Products. Specialty Packaging Products, and Chemistries. 2 Before allocation of corporate expenses of ~$8.9M. 3 Earnings Before Interest, Taxes,

  8. Slide 8: Recent Acquisition – Byrne Medical

    Recent Acquisition – Aug 1, 2011 Endoscopy: Facilitate Accelerated Global Growth Minntech subsidiary acquired the assets of Byrne Medical, Inc. for $90.0M in cash and $10.0M in stock, plus $10.0M potential earnout Pre-acquisition revenues of ~$38.6M and EBIT of $11.5M Complementary: Further bolster

  9. Slide 9: Endoscopy Segment: Complementary Businesses

    9 Medivators Plus Byrne Medical Endoscopy Segment: Complementary Businesses Intercept Wipes Veriscan Scope Buddy Intercept CER/DSD/ Advantage Rapicide Rapicide PA PROCEDURE ROOM Byrne Medical Products Treatment Room Physicians & Nurses Medivators Endoscope Reprocessing Products Principally in Post-P

  10. Slide 10: Business Overview by Product, Customer, Channel

    10 Cantel Medical Corp. Business Overview by Product, Customer, Channel Infection Prevention & Control Focus Healthcare & Life Sciences Orientation NYSE: CMN Renal / Dialysis Equipment, Sterilants, Consumables, Service Endoscopy Equipment, Disinfectants, Consumables, Service Dental Disposables Water

  11. Slide 11: Experienced Executive Team

    11 Cantel Medical Corp. Experienced Executive Team Andrew A. Krakauer President & CEO Former President of Ohmeda Medical (Division of Instrumentarium/GE) Over 20 years of healthcare experience Joined Cantel in 2004 as COO Craig A. Sheldon SVP, Chief Financial Officer & Treasurer Formerly with Ernst

  12. Slide 12: Strong Performance Over the Past Two Years

    12 Cantel Medical Corp. Strong Performance Over the Past Two Years 1 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 2 Reflects abnormally large impact due to Novel H1N1 (“Swine”) flu sales of facemasks. 3 Last Twelve Months Cash flow from Operations less

  13. Slide 13: Historical Income Statement Highlights

    13 Cantel Medical Corp. Historical Income Statement Highlights 1 Reflects continuing operations and excludes any historical impact of Carsen Endoscopy & Surgical business. 2 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 3 Equivalent to “Income from Cont

  14. Slide 14: Capacity for Continued Investment

    14 Cantel Medical Corp. Capacity for Continued Investment 1 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 2 Reclassified long-term debt as current liability due to expiration date of revolver. 3 Impact of $96M in debt used to acquired Byrne Medical. Sal

  15. Slide 15: Significant Upside Growth Opportunities

    15 Cantel Medical Corp. Significant Upside Growth Opportunities Substantial Sales & Marketing investments in core FY’09-FY’11 Substantial increase in R&D spending in FY’11 High-Margin Liquid Chemical Germicides (LCG) New chemistry development capabilities began mid-FY’10, accelerating in FY’11, to y

  16. Slide 16: Significant Upside Growth Opportunities

    16 Cantel Medical Corp. Significant Upside Growth Opportunities Acquisitions: 3 recent acquisitions, one in each core segment Byrne Medical has leadership position to drive a large, global market conversion to profitable disposable endoscopy components Continue solid integration and advancement on t

  17. Slide 17: Recent Acquisition in FY'11: Water Treatment

    Recent Acquisition in FY’11 Water Treatment Mar Cor Purification subsidiary acquired Gambro’s U.S. water treatment business (Oct 6, 2010) for $23.7M in cash. Pre-acquisition revenues of ~$14.0M. Strategic value akin to success of Mar Cor’s acquisition of GE’s Dialysis Water Business in March 2007. T

  18. Slide 18: Recent Acquisition in FY'11: Healthcare Disposables

    Recent Acquisition in FY’11 Healthcare Disposables Crosstex Int’l subsidiary acquired ConFirm Monitoring Systems’ sterility assurance business (Feb 14, 2011) for $7.5M in cash1. Pre-acquisition revenues of ~$4.0M. Product line extension to Crosstex’ key sterilization product category Position: #1 pl

  19. Slide 19: Strategic Evolution

    Cantel Medical Corp. Strategic Evolution FY’04 – FY’08: Acquire and Define Infection Prevention & Control (IPC) Portfolio FY’09 – FY’10: Substantial Operational and P&L Improvement, while Investing in Sales & Marketing FY’11: Leverage Sales & Marketing and Drive R&D Investments. Close 1-2 Key Acquis

  20. Slide 20: Formula: Acquire, Improve Businesses, Reload

    Cantel Medical Corp. Formula: Acquire, Improve Businesses, Reload CAGR% 18% 23% ($25) $0 $25 $50 $75 $100 $125 $150 $175 $200 $225 $250 $275 $300 $325 $350 $ Millions Net Sales $94.0 $123.0 $137.2 $192.2 $219.0 $249.4 $260.1 $274.0 $344.0 EBITDAS $11.3 $14.0 $19.4 $26.5 $28.6 $31.8 $42.0 $47.5 $59.8

  21. Slide 21: Strategic Objectives Remain Focused within Infection Prevention & Control

    21 Cantel Medical Corp. Strategic Objectives Remain Focused within Infection Prevention & Control Near-term build a profitable $500 Million Specialty Business... setting the strategy for $1 Billion Achieve accelerated growth and profits from the three recent acquisitions Invest in higher technology,

  22. Slide 22: Summary

    22 Cantel Medical Corp. Summary Global, Growing ~$35B Market in Infection Prevention & Control Pure-play focus Fragmented nature creates opportunities for further growth and expansion $345M NYSE Specialty Infection Prevention & Control Leader1 Strong, recession-buffered core business with high futur

  23. Slide 23: Infection Control Matters

    Cantel Medical Corp. (NYSE: CMN) Infection Control Matters™ CROSSTEX

Cantel Medical — Investor Presentation (September 2011) on 6ix